OncoMatch/Clinical Trials/NCT06771518
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Is NCT06771518 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Atezolizumab 1200 mg e.v. q21 for small cell lung cancer.
Treatment: Atezolizumab 1200 mg e.v. q21 — Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage EXTENDED DISEASE
Extended disease at the time of first line oncological treatment
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy — first line
chemoimmunotherapy according to the Impower 133 scheme
Cannot have received: radiation therapy
Exception: thoraco-mediastinal level only
Previous radiotherapy treatment at the thoraco-mediastinal level
Lab requirements
Blood counts
Haematological toxicity ≤ G1
Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify